The Affordable Care Act created a pathway for FDA approval of biosimilars, and the agency has been developing the rules that will govern this new area. Biocom has organized a discussion about the challenges state and federal authorities face in creating a system that will work for both biosimilar innovators and manufacturers. This session offers an opportunity to learn what the real potential of this segment will be as these products come closer to commercialization. More information and online registration is here.